Expert insights. Personalized for you.
Branding Related Topics 
Scienmag
JUNE 27, 2022
When liberals and conservatives receive gift cards for politicized brands that clash with their own views, they are less appreciative of the gift-giver’s gesture, new research indicates. Latest News Brands cards dampen gift Gratitude politicalized recipientsPULLMAN, Wash.
Drug Patent Watch
JUNE 29, 2022
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JUNE 28, 2022
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
MAY 12, 2022
ATLANTA, May 12, 2022 – New research led by scientists at the American Cancer Society (ACS) shows the need for continued surveillance of the changes in shopping interest and sales for Puff Bar, the most preferred brand of electronic cigarettes or e-cigarettes among youth in the United States.
Bio Pharma Dive
FEBRUARY 28, 2022
Self-care and the resulting increased use of over-the-counter (OTC) medications is a growing global trend
Scienmag
SEPTEMBER 30, 2021
Whether they’re beefing on billboards or sparring on social media, big brands are known for taking jabs at their competitors (see the famous “Get a Mac” ads or “the chicken sandwich wars”). Social & Behavioral Science boost Brands praising reputations rivals sales
Pharma Phorum
DECEMBER 14, 2020
In today’s fast-paced world how do you make sure your brand messages resonate with your customers and, if they do, how can your brand become even more remarkable? How healthy is your brand? The best treatment for brand diseases is ‘action copywriting’. of the brand.
Drug Patent Watch
JULY 1, 2022
Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 10, 2022
DrugPatentWatch developed this course to help users better understand the complexities and common strategies around brand erosion and generic entry. The post Free Online Course on Drug Patents, Generic and Branded Drugs appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Phorum
AUGUST 13, 2020
How the COVID-19 pandemic is forging pharmaceutical brands into better shape. Day by day it becomes clearer that some brands are coming through the pandemic in better shape than ever. Non-pharma brands leading by example.
Drug Patent Watch
OCTOBER 4, 2021
The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions. This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference.
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
XTalks
MARCH 8, 2022
Women-owned food brands have made some remarkable strides in the food and beverage industry. To celebrate Women’s History Month and International Women’s Day on March 8, there are countless woman-owned-and-operated food brands to support beyond the month of March.
|
Drug Patent Watch
FEBRUARY 1, 2022
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
XTalks
JULY 1, 2021
Moderna has won approval from the European Medicines Association (EMA) for branding its COVID-19 vaccine with the name Spikevax. With the approval, Moderna’s Spikevax joins Pfizer-BioNTech’s Comirnaty and AstraZeneca’s Vaxzevria with European brand-name approvals.
BioTech 365
MARCH 18, 2022
Simply Better Brands Corp. Completes Business Acquisition Simply Better Brands Corp. Completes Business Acquisition VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) — Simply Better Brands Corp?. the “Company” or “Simply Better Brands?”) (TSX Venture: SBBC, OTCQB: PKANF)?, announces today … Continue reading → GlobeNewswire
Pharma Phorum
FEBRUARY 11, 2021
The healthcare brand consultancy Branding Science has opened a new office in Germany. . “With its diverse and creative atmosphere, Berlin is a perfect fit for Branding Science and our company culture!” News Sales and Marketing Branding Science comms
Drug Patent Watch
DECEMBER 17, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
JUNE 15, 2022
MINNEAPOLIS – The cost of brand-name drugs for epilepsy increased by 277% from 2010 to 2018, according to a study published in the June 15, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.The cost of generic drugs for epilepsy decreased by 42% over the same period. Brand-name drugs made […].
FDA Law Blog
AUGUST 29, 2021
This policy, announced by then Associate Attorney General Rachel Brand in 2018 was referred to as the Brand Memo. As a matter of administrative law, the Brand Memo made good sense from the perspective of FDA-regulated industry, as we described here. By Anne K.
Intouch Solutions
JUNE 10, 2022
We unveiled our new brand – EVERSANA INTOUCH – and had celebrations across many of our offices to mark the occasion with some fun and cameraderie! Our new brand is the next step in our journey of joining EVERSANA , which began last year.
Drug Patent Watch
APRIL 11, 2022
Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
APRIL 11, 2022
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
XTalks
DECEMBER 3, 2021
Spoiler Alert , a Boston-based software company that helps perishable consumer packaged goods (CPG) brands manage excess inventory, announced on Wednesday that it raised $11 million in a series A funding round.
BioTech 365
JULY 1, 2022
US Branded Generics Market to Reach $172.03 Million in 2022 – ResearchAndMarkets.com US Branded Generics Market to Reach $172.03 Million in 2022 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Branded Generics Market Research … Continue reading → Business WireMillion by 2027 from $77.9 Million by 2027 from $77.9
BioTech 365
MAY 3, 2022
Chalice Brands Ltd. Announces Late Filing of Annual Financial Statements Chalice Brands Ltd. May 03, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”) … Continue reading → GlobeNewswireAnnounces Late Filing of Annual Financial Statements PORTLAND, Ore.,
Drug Patent Watch
JULY 14, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
BioTech 365
MAY 6, 2022
Simply Better Brands Corp. Announces Shares For Debt Transaction Simply Better Brands Corp. Announces Shares For Debt Transaction VANCOUVER, British Columbia, May 06, 2022 (GLOBE NEWSWIRE) — Simply Better Brands Corp. (“SBBC” or the “Company“) (TSX Venture: SBBC, OTCQB: PKANF) … Continue reading → GlobeNewswire
Drug Patent Watch
MAY 13, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
BioTech 365
JUNE 23, 2022
Chalice Brands Ltd. Announces Appointment of Richard Lindsay as Interim Chief Financial Officer Chalice Brands Ltd. June 23, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. Announces Appointment of Richard Lindsay as Interim Chief Financial Officer PORTLAND, Ore., CSE: CHAL) (OTCQB: … Continue reading → GlobeNewswire
Pharma Phorum
JANUARY 13, 2022
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study.
Drug Patent Watch
APRIL 2, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
BioTech 365
SEPTEMBER 2, 2020
–(BUSINESS WIRE)–CATO SMS unveiled its new brand today, revealing an updated look and logo capturing the company’s powerful offering following the merger of CATO Research, LLC and Specialized Medical Services-oncology BV (SMS-oncology). CARY, N.C.–(BUSINESS
Intouch Solutions
SEPTEMBER 22, 2020
They can be gatekeepers to their audiences and authenticators of brand messaging, serving as extended voices of a brand. The post Bringing Health Influencers Into Your Brand appeared first on Intouch Solutions. Today, the voices of influencers are vital.
Drug Patent Watch
MARCH 13, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
FEBRUARY 11, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
BioTech 365
NOVEMBER 2, 2020
MOMI Brands, Inc. Closes $1M Seed Round MOMI Brands, Inc. –(BUSINESS WIRE)–#babyproducts—MOMI Brands, Inc. Closes $1M Seed Round Former Medela president launches startup to commercialize new breast pump and infant feeding technologies WINSTON-SALEM, N.C.–(BUSINESS
Drug Patent Watch
DECEMBER 9, 2021
Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
JUNE 22, 2021
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. The post New patent expiration for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MAY 16, 2021
Product Name: Doctor’s Ed Solution – Brand New Angle. Doctor’s Ed Solution – Brand New Angle is backed with a 60 Day No Questions Asked Money Back Guarantee.
The Pharma Data
MAY 13, 2021
Product Name: Brand New "primal" Beauty Offer For Women! Click here to get Brand New "primal" Beauty Offer For Women! Brand New "primal" Beauty Offer For Women! Description: Click here to get Brand New "primal" Beauty Offer For Women!
BioTech 365
JUNE 15, 2022
Chalice Brands Ltd. Announces Delay in Filing of Annual Financial Statements Chalice Brands Ltd. June 15, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. Announces Delay in Filing of Annual Financial Statements PORTLAND, Ore., CSE: CHAL) (OTCQB: CHALF) (the “Company” or … Continue reading → GlobeNewswire
BioTech 365
AUGUST 26, 2021
Chalice Brands Ltd. Continues Sequential Revenue Growth Chalice Brands Ltd. 26, 2021 (GLOBE NEWSWIRE) — Chalice Brands … Continue reading → GlobeNewswireContinues Sequential Revenue Growth Reports Second Quarter 2021 Revenues of $6.9 Million and Third Consecutive Quarter of Positive Adjusted EBITDA(1) PORTLAND, Ore.,
83 
Let's personalize your content